Actively Recruiting
Special Care Patterns for Elderly Head-and-Neck Squamous Cell Carcinoma Patients Undergoing Radiotherapy
Led by University Hospital Freiburg · Updated on 2025-03-25
1500
Participants Needed
18
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital Freiburg
Lead Sponsor
C
Charite University, Berlin, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating treatment outcomes in elderly patients aged 65 years and older with locally advanced head-and-neck squamous cell carcinomas (HNSCC) involving the oral cavity, oropharynx, hypopharynx, or larynx. The study aims to determine how definitive (chemo-)radiotherapy affects overall survival and progression-free survival in this vulnerable population, considering factors like age, performance status, and comorbidities. This retrospective multinational multicenter study addresses the limited evidence on optimal care for these patients. The study observes patients who have undergone definitive (chemo-)radiotherapy since 2005, focusing on modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and varying chemotherapy schedules, including weekly cisplatin. It assesses the impact of these treatments on survival outcomes and investigates the role of concomitant chemotherapy in this elderly cohort. Participants' medical records are reviewed to collect data on overall survival up to five years and progression-free survival up to five years after treatment initiation. Researchers analyze patient characteristics, treatment details, and outcomes to understand the influence of therapy choices on survival. The study involves no new interventions or procedures, relying on existing clinical data from multiple centers.
CONDITIONS
Brief Title
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 65 years or older at the time of definitive (chemo-)radiotherapy
- Diagnosed with locoregionally advanced (cT3-4 and/or cN+) head-and-neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
- Primary treatment with definitive (chemo-)radiotherapy since 2005
You will not qualify if you...
- Receiving adjuvant (chemo-)radiotherapy
- History of previous head-and-neck cancers or prior radiotherapy in the head-and-neck region
- Presence of distant metastases at the start of (chemo-)radiotherapy (cM1)
- Head-and-neck squamous cell carcinomas of the nasopharynx, salivary glands, skin, or unknown primary site
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed to assess overall survival and progression-free survival after their definitive (chemo-)radiotherapy treatment.
Periodic visits depending on clinical follow-up schedules
Trial Site Locations
Total: 18 locations
1
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287
Completed
2
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10017
Completed
3
Department of Radiation Oncology, Case Western Reserve University
Cleveland, Ohio, United States, 10900
Completed
4
Division of Radiation Oncology, The Ohio State University Wexner
Columbus, Ohio, United States, 43201
Completed
5
Radiation Oncology Department, German Oncology Center
Limassol, Cyprus
Completed
6
Brno University Hospital
Brno, Czechia
Completed
7
Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin
Berlin, Germany
Completed
8
Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, Germany
Completed
9
Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main
Frankfurt, Germany
Completed
10
University of Giessen
Giessen, Germany
Completed
11
Martin-Luther-Universität Halle-Wittenberg
Halle, Germany
Completed
12
Jena University Hospital
Jena, Germany
Actively Recruiting
13
Department of Radiation Oncology, University Hospital Schleswig-Holstein
Kiel, Germany
Completed
14
Department of Radiation Oncology, University Medical Center Leipzig
Leipzig, Germany
Completed
15
Department of Radiation Oncology, University Medical Center Mainz
Mainz, Germany
Completed
16
Department of Radiation Oncology, University Hospital, LMU Munich
Munich, Germany
Completed
17
Department of Radiation Oncology, University Hospital Würzburg
Würzburg, Germany
Completed
18
Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH)
Zurich, Switzerland
Completed
Research Team
A
Alexander Rühle, MD, MHBA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here